Nasdaq GlobeNewswire

Apricus Biosciences Announces the Launch of Vitaros® in the Czech Republic and Slovakia by Recordati

Del

SAN DIEGO, 2016-09-21 13:00 CEST (GLOBE NEWSWIRE) --

Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the launch of Vitaros®, Apricus’ novel on-demand topical cream for the treatment of erectile dysfunction (ED), in the Czech Republic and Slovakia by Recordati.

Richard Pascoe, Chief Executive Officer of Apricus, commented, “We are pleased to announce the launch of Vitaros in these important ED markets by our partner Recordati.  With these launches, Vitaros is now commercially available in nine European countries.  Moreover, we expect additional approvals and product launches later this year and early next year by our commercialization partners.  Looking forward, our key strategic goals continue to be achieving profitability through Vitaros revenue growth and obtaining Vitaros FDA approval in the United States in 2017.”

In February 2014, Apricus signed an exclusive license agreement with Recordati to market Vitaros in Spain, Russia, Turkey, Ireland and certain other European and African countries and received an upfront payment of $2.4 million.  Under the terms of the agreement, Apricus is eligible to receive up to approximately $39.7 million from Recordati in additional milestones, plus double-digit tiered royalties in the ten to twenty percent range based on Recordati’s net sales of the product in the territory.

Vitaros is a new entrant into these ED treatment markets, offering a product profile making it appealing to certain patients.  Vitaros is a topical ED cream that delivers rapid onset (generally five to thirty minutes) and treatment duration of approximately one to two hours.  Vitaros’ local delivery provides an alternative for patients, but particularly those with complications that preclude them from using the orally delivered systemic treatments or who prefer to avoid the injectable forms of alprostadil.

About Recordati

Established in 1926, Recordati is an international pharmaceutical group, listed on the Italian Stock Exchange (Bloomberg REC IM), with a total staff of around 4,000, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Recordati is headquartered in Milan, Italy, with operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey, in the United States of America and in North Africa. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new drug entities within the urogenital therapeutic area and of treatments for rare diseases.

For further information, please visit the Recordati website: www.recordati.com.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus’ commercial product, Vitaros®, for the treatment of erectile dysfunction, is approved in Europe, part of the Middle East and Canada and is being commercialized in several countries in Europe. In September 2015, Apricus in-licensed the U.S. development and commercialization rights for Vitaros from Allergan. Apricus’ marketing partners for Vitaros include Recordati Ireland Ltd. (Recordati), Ferring International Center S.A. (Ferring Pharmaceuticals), Laboratoires Majorelle, Bracco S.p.A., Mylan NV and Elis Pharmaceuticals Ltd. Apricus currently has one active product candidate, RayVa, its product candidate for the treatment of the circulatory disorder Raynaud’s phenomenon.

For further information on Apricus, visit http://www.apricusbio.com

*Vitaros® is a registered trademark of NexMed International Limited.  Such trademark is registered in certain countries throughout the world and pending registration in the United States.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act, as amended. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things: references to potential Vitaros approvals and product launches by Apricus’ commercial partners in additional countries and the timing thereof; the potential for the product to achieve commercial success generally or in any specific territory, including the Czech Republic and Slovakia, and for Apricus to receive future milestone and royalty revenue; the ability of Apricus to achieve profitability based on Vitaros revenue growth; and the timing of approval, if any, by the Food and Drug Administration (FDA) of Vitaros in the United States. Actual results could differ from those projected in any forward-looking statements due to a variety of reasons that are outside of Apricus’ control, including, but not limited to: Apricus’ dependence on its commercial partners to carry out the commercial launch or grow sales of Vitaros in various territories, such as Recordati in its territory, and obtain additional product approvals; competition in the ED market and other markets in which Apricus and its partners operate; Apricus’ ability to obtain and maintain intellectual property protection for the product; Apricus’ ability to raise additional funding that it may need to continue to pursue its commercial and business development plans; Apricus’ ability to obtain FDA and other requisite governmental approval for Vitaros; the fluctuation of currency exchange rates; the potential for adverse reactions to the product; Apricus’ ability to negotiate and enter into acceptable terms for new licensing agreements; and market conditions. These forward-looking statements are made as of the date of this press release, and Apricus assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors set forth in Apricus’ most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the SEC's website at www.sec.gov or without charge from Apricus.

         Contact:
         Matthew Beck
         mbeck@troutgroup.com
         The Trout Group LLC
         (646) 378-2933

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Algeco Scotsman Announces Debt Package for Refinancing, Acquisition of Touax Solutions Modulaires SAS and Exercise of Put Option10.12.2017 23:14Pressemelding

BALTIMORE, Md., Dec. 10, 2017 (GLOBE NEWSWIRE) -- Algeco/Scotsman Holding S.à r.l. (together with its subsidiaries, the "Algeco Group") today announced that a finance special purpose vehicle that will be a subsidiary of the Algeco Group has entered into a senior debt package arranged by a syndicate of lending institutions and a preferred stock facility with a group of other financing providers. The proceeds of this financing, or any debt issued in lieu of the loans under the facilities (which replacement debt could be in the form of loans, securities or other debt instruments, may be publicly or privately placed and may be denominated in euros or US dollars), will be used to refinance the existing capital structure of the Algeco Group, including its existing Senior Secured Notes due 2018 and existing Senior Unsecured Notes due 2019. In connection with this refinancing, a lending syndicate will provide a new $400 million senior secured asset backed facility. The debt package is continge

Elemica Wins Green Supply Chain Award8.12.2017 19:54Pressemelding

WAYNE, Pa., Dec. 08, 2017 (GLOBE NEWSWIRE) -- Elemica, the leading Business Network for the process industries, announces winning the Supply & Demand Chain Executive Green Supply Chain Award for 2017. This is Elemica's 9th consecutive win of this prestigious award that recognizes small, mid-size and large enterprises that leveraged green practices and solutions to further drive sustainable improvements in their supply chain. Elemica was chosen for helping clients improve and achieve measurable sustainability goals through the automation of manual processes, eliminating the use of paper and optimizing transportation processes through carrier collaboration and automated processes that reduce mileage. "This is a great honor for Elemica - recognition for nine consecutive years for helping clients meet their green and sustainability goals," said John Blyzinskyj, CEO of Elemica. "By utilizing Elemica's integrated cloud-based logistics and transportation products, customers have lowere

Constellation Brands to Report Third Quarter Fiscal 2018 Financial Results; Host Conference Call January 5, 20187.12.2017 22:37Pressemelding

VICTOR, N.Y., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Constellation Brands, Inc. (NYSE:STZ) (NYSE:STZ.B), a leading beverage alcohol company, announced today it will report financial results for its fiscal third quarter ended November 30, 2017, on Friday, January 5, 2018, before the open of the U.S. markets. A conference call to discuss the financial results and outlook will be hosted by President and Chief Executive Officer Rob Sands and Executive Vice President and Chief Financial Officer David Klein at 10:30 a.m. eastern time, January 5, 2018.  The conference call can be accessed by dialing +973-935-8505 beginning at 10:20 a.m. (eastern). A live, listen-only webcast of the conference call will be available on the company's website, www.cbrands.com, under the Investors section. Financial information discussed on the conference call, and a reconciliation of reported (GAAP) financial measures with comparable or non-GAAP financial measures, will also be available on the company's websi

CTI Clinical Trial and Consulting Services Announces Acquisition of Eurotrials7.12.2017 21:00Pressemelding

COVINGTON, Ky., Dec. 07, 2017 (GLOBE NEWSWIRE) -- CTI Clinical Trial and Consulting Services (CTI), a global, privately held, full-service contract research organization announces the acquisition of Eurotrials, a full-service contract research organization, with more than 20 years of experience, and strong local expertise in Europe and Latin America. The acquisition strengthens CTI's existing Real World Evidence business, adding significant presence and expertise in Europe and Latin America. Eurotrials has offices in Argentina, Brazil, Chile, Mexico, Peru, Portugal and Spain, covering over 15 countries in both regions. Eurotrials provides an extensive array of services from early- to late-stage research as well as product support in accordance with global and specific regional requirements.  Additionally, the Eurotrials footprint augments CTI's current reach, enabling CTI to better serve clients and global programs. "We are excited to join our companies together t

DigitalTown Announces Global Launch of CityShares7.12.2017 19:29Pressemelding

Local Ownership Model for City Platform Cooperatives built on Blockchain SEATTLE, Dec. 07, 2017 (GLOBE NEWSWIRE) -- DigitalTown, Inc. (OTC PINK:DGTW), the leading provider of People-centric Solutions for Smart Cities, announced today the beginning of the free claim period for CityShares, or fractional interests, in its Smart City platforms across nearly 4 million cities, towns and villages around the world. The announcement makes it possible for any city to become a Smart City based on the DigitalTown platform. A PowerPoint presentation accompanying this announcement is available at  http://www.globenewswire.com/NewsRoom/AttachmentNg/6287d2a9-d481-4e0e-a162-9c3f224daeb1 Since the introduction of DigitalTown in London in June 2017, management at DigitalTown has been in discussions with stakeholders in cities and towns around the world to introduce its flagship Platform Cooperative for Cities. The groundbrea

Crown Bioscience Releases Scientific Posters Detailing Innovations in Preclinical Cancer Pharmacology7.12.2017 16:45Pressemelding

Presentation of Posters by Expert Scientists Now Available On-Demand on Crown Bioscience's Website  https://www.crownbio.com/eortc17-posters SANTA CLARA, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) --  Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, releases scientific posters narrated by leading scientists. These posters were presented at the recent AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and are now available on-demand on Crown Bioscience's website,  https://www.crownbio.com/eortc17-posters. Crown Bioscience presented more than a dozen scientific posters describing innovations in the field of preclinical cancer research at AACR-NCI-EORTC 2017. The most compelling work is now available

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom